Business Description
Kyverna Therapeutics Inc
NAICS : 541713
SIC : 2834
ISIN : US5019761049
Total Employee Number:
129Description
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.01 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | -0.22 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -49.5 | |||||
3-Year EPS without NRI Growth Rate | -48.1 | |||||
3-Year FCF Growth Rate | -34.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 11.62 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 34.71 | |||||
9-Day RSI | 43.97 | |||||
14-Day RSI | 47.09 | |||||
3-1 Month Momentum % | -14.41 | |||||
6-1 Month Momentum % | -7.93 | |||||
12-1 Month Momentum % | 114.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.15 | |||||
Quick Ratio | 8.15 | |||||
Cash Ratio | 7.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.9 | |||||
Shareholder Yield % | -1.91 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -79.13 | |||||
ROA % | -63.83 | |||||
ROIC % | -754.77 | |||||
3-Year ROIIC % | -2033.64 | |||||
ROC (Joel Greenblatt) % | -2050.88 | |||||
ROCE % | -73.79 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.63 | |||||
Price-to-Tangible-Book | 2.63 | |||||
EV-to-EBIT | -2.02 | |||||
EV-to-EBITDA | -2.04 | |||||
EV-to-Forward-Revenue | 312.85 | |||||
EV-to-FCF | -2.08 | |||||
| Price-to-Net-Current-Asset-Value | 2.85 | |||||
| Price-to-Net-Cash | 2.94 | |||||
Earnings Yield (Greenblatt) % | -49.5 | |||||
FCF Yield % | -29.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KYTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kyverna Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.28 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 65.28 | ||
| 14-Day RSI | 47.09 | ||
| 14-Day ATR ($) | 0.668333 | ||
| 20-Day SMA ($) | 8.608 | ||
| 12-1 Month Momentum % | 114.57 | ||
| 52-Week Range ($) | 2.8 - 13.67 | ||
| Shares Outstanding (Mil) | 60.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kyverna Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kyverna Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 122 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 30 days | ||
| General meeting for 2025 | 2026-05-29 11:00 | 8.65 (+0.58%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 10.34 (+10.35%) | ||
| Kyverna AAN Conference Call | 2026-04-22 07:00 | 9.71 (-13.69%) | ||
| Annual report for 2025 | 2026-03-26 | 7.87 (+0.77%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 7.87 (+0.77%) | ||
| Guidance call for 2026 | 2026-03-10 | 8.40 (+4.35%) | ||
| Guidance call for 2026 | 2026-03-09 11:20 | 8.10 (-2.99%) | ||
| Guidance call for 2026 | 2026-01-14 09:45 | 8.66 (+3.96%) |
Show
Entries
Kyverna Therapeutics Inc Frequently Asked Questions
What is Kyverna Therapeutics Inc(KYTX)'s stock price today?
The current price of KYTX is $8.49. The 52 week high of KYTX is $13.67 and 52 week low is $2.80.
When is next earnings date of Kyverna Therapeutics Inc(KYTX)?
The next earnings date of Kyverna Therapeutics Inc(KYTX) is 2026-08-12 Est..
Does Kyverna Therapeutics Inc(KYTX) pay dividends? If so, how much?
Kyverna Therapeutics Inc(KYTX) does not pay dividend.
Guru Commentaries on NAS:KYTX
No articles.
Press Release
Articles on Kyverna Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers